Mumps - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/05/15
頁 數：34頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Mumps - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Mumps - Pipeline Review, H1 2014’, provides an overview of the Mumps’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Mumps, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mumps and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Mumps
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Mumps and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Mumps products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Mumps pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Mumps
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Mumps pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Mumps - Pipeline Review, H1 2014’, provides an overview of the Mumps’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Mumps, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mumps and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Mumps
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Mumps and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Mumps products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Mumps pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Mumps
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Mumps pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Mumps Overview 6
Therapeutics Development 7
Pipeline Products for Mumps - Overview 7
Pipeline Products for Mumps - Comparative Analysis 8
Mumps - Therapeutics under Development by Companies 9
Mumps - Therapeutics under Investigation by Universities/Institutes 10
Mumps - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Mumps - Products under Development by Companies 14
Mumps - Products under Investigation by Universities/Institutes 15
Mumps - Companies Involved in Therapeutics Development 16
GlaxoSmithKline plc 16
Zydus Cadila Healthcare Limited 17
Beijing Tiantan Biological Products Co., Ltd. 18
Mumps - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Combination Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 22
Drug Profiles 24
measles, mumps and rubella vaccine (live) - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Vaccine for Live Measles, Mumps and Rubella - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Live Attenuated Vaccine For Mumps - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
MMR + Varicella Vaccine - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Mumps Vaccine - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Mumps - Recent Pipeline Updates 29
Mumps - Dormant Projects 30
Mumps - Product Development Milestones 31
Featured News & Press Releases 31
Jun 13, 2012: UGA researcher developing new vaccine to fight resurging mumps virus 31
Mar 15, 2012: CHMP Adopts Positive Opinion Recommending Variation To Terms Of Marketing Authorization For Proquad 32
Appendix 33
Methodology 33
Coverage 33
Secondary Research 33
Primary Research 33
Expert Panel Validation 33
Contact Us 34
Disclaimer 34
List of Tables
Number of Products under Development for Mumps, H1 2014 7
Number of Products under Development for Mumps - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Number of Products under Investigation by Universities/Institutes, H1 2014 10
Comparative Analysis by Late Stage Development, H1 2014 11
Comparative Analysis by Clinical Stage Development, H1 2014 12
Comparative Analysis by Early Stage Development, H1 2014 13
Products under Development by Companies, H1 2014 14
Products under Investigation by Universities/Institutes, H1 2014 15
Mumps - Pipeline by GlaxoSmithKline plc, H1 2014 16
Mumps - Pipeline by Zydus Cadila Healthcare Limited, H1 2014 17
Mumps - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H1 2014 18
Assessment by Monotherapy Products, H1 2014 19
Assessment by Combination Products, H1 2014 20
Number of Products by Stage and Route of Administration, H1 2014 21
Number of Products by Stage and Molecule Type, H1 2014 23
Mumps Therapeutics - Recent Pipeline Updates, H1 2014 29
Mumps - Dormant Projects, H1 2014 30
List of Figures
Number of Products under Development for Mumps, H1 2014 7
Number of Products under Development for Mumps - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Clinical Stage Development, H1 2014 12
Comparative Analysis by Early Stage Products, H1 2014 13
Assessment by Monotherapy Products, H1 2014 19
Number of Products by Stage and Top 10 Route of Administration, H1 2014 21
Number of Products by Top 10 Molecule Type, H1 2014 22
Number of Products by Stage and Top 10 Molecule Type, H1 2014 23
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Mumps Overview 6
Therapeutics Development 7
Pipeline Products for Mumps - Overview 7
Pipeline Products for Mumps - Comparative Analysis 8
Mumps - Therapeutics under Development by Companies 9
Mumps - Therapeutics under Investigation by Universities/Institutes 10
Mumps - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Mumps - Products under Development by Companies 14
Mumps - Products under Investigation by Universities/Institutes 15
Mumps - Companies Involved in Therapeutics Development 16
GlaxoSmithKline plc 16
Zydus Cadila Healthcare Limited 17
Beijing Tiantan Biological Products Co., Ltd. 18
Mumps - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Combination Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 22
Drug Profiles 24
measles, mumps and rubella vaccine (live) - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Vaccine for Live Measles, Mumps and Rubella - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Live Attenuated Vaccine For Mumps - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
MMR + Varicella Vaccine - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Mumps Vaccine - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Mumps - Recent Pipeline Updates 29
Mumps - Dormant Projects 30
Mumps - Product Development Milestones 31
Featured News & Press Releases 31
Jun 13, 2012: UGA researcher developing new vaccine to fight resurging mumps virus 31
Mar 15, 2012: CHMP Adopts Positive Opinion Recommending Variation To Terms Of Marketing Authorization For Proquad 32
Appendix 33
Methodology 33
Coverage 33
Secondary Research 33
Primary Research 33
Expert Panel Validation 33
Contact Us 34
Disclaimer 34
List of Tables
Number of Products under Development for Mumps, H1 2014 7
Number of Products under Development for Mumps - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Number of Products under Investigation by Universities/Institutes, H1 2014 10
Comparative Analysis by Late Stage Development, H1 2014 11
Comparative Analysis by Clinical Stage Development, H1 2014 12
Comparative Analysis by Early Stage Development, H1 2014 13
Products under Development by Companies, H1 2014 14
Products under Investigation by Universities/Institutes, H1 2014 15
Mumps - Pipeline by GlaxoSmithKline plc, H1 2014 16
Mumps - Pipeline by Zydus Cadila Healthcare Limited, H1 2014 17
Mumps - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H1 2014 18
Assessment by Monotherapy Products, H1 2014 19
Assessment by Combination Products, H1 2014 20
Number of Products by Stage and Route of Administration, H1 2014 21
Number of Products by Stage and Molecule Type, H1 2014 23
Mumps Therapeutics - Recent Pipeline Updates, H1 2014 29
Mumps - Dormant Projects, H1 2014 30
List of Figures
Number of Products under Development for Mumps, H1 2014 7
Number of Products under Development for Mumps - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Clinical Stage Development, H1 2014 12
Comparative Analysis by Early Stage Products, H1 2014 13
Assessment by Monotherapy Products, H1 2014 19
Number of Products by Stage and Top 10 Route of Administration, H1 2014 21
Number of Products by Top 10 Molecule Type, H1 2014 22
Number of Products by Stage and Top 10 Molecule Type, H1 2014 23
